ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models
Molecular Therapy Oncology · 2026-12 · 34 (4) · 201367
DOI: 10.1016/j.omton.2026.201367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-12. Verfasst von Richard T Baugh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Wellcome Trust Brenner Building, Beckett Street, Leeds LS9 …. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sarcoma UK, Bone Cancer Research Trust.
Abstract (Originalsprache)
Ewing sarcoma (EWS) is a rare pediatric malignancy of the bone and soft tissue and requires better-tolerated and improved therapies. Oncolytic viruses (OVs) preferentially replicate in cancer cells, causing oncolysis, and activate both innate and adaptive anti-tumor immunity. Thus, OVs have the potential to generate long-lasting, systemic anti-cancer activity. Using a unique panel of patient-derived EWS cultures (PDES), recently derived from patient tumors at diagnosis and relapse, we have identified oncolytic coxsackievirus A21 (CVA21) as a candidate therapeutic OV in EWS, due to its high oncolytic activity and immune stimulation. PDES, unlike established EWS cell lines, expressed intercellular adhesion molecule-1 (ICAM-1), the CVA21 viral entry receptor, and were sensitive to CVA21-mediated oncolysis. Treatment with known ICAM-1 inducers, including tumor necrosis factor (TNF) and the clinically deliverable agent all-trans retinoic acid (ATRA), increased ICAM-1 expression and enhanced CVA21-induced oncolysis. Importantly, while CVA21 replication and oncolysis were inhibited by antiviral type I interferon, pre-treatment with ICAM-1 inducers (or CVA21-induced immune-mediated cytokines) overcame this inhibition. In addition to direct oncolysis, co-culture of CVA21-infected PDES with peripheral blood mononuclear cells (PBMCs) stimulated significant immune-mediated killing. This study presents pre-clinical evaluation of CVA21 using clinically relevant PDES samples and identifies CVA21 as a promising candidate for EWS immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Wellcome Trust Brenner Building, Beckett Street, Leeds LS9 7TF, UK.
Förderung
- Sarcoma UK
- Bone Cancer Research Trust
Zitieren
APA
Baugh, R. T., Barr, T., Roundhill, E. A., Ismail, F., Volpato, M., Cook, G. P., Burchill, S. A., & Errington-Mais, F. (2026). ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models. Molecular Therapy Oncology, 34(4), 201367. https://doi.org/10.1016/j.omton.2026.201367
Vancouver
Baugh RT, Barr T, Roundhill EA, Ismail F, Volpato M, Cook GP, et al. ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models. Molecular Therapy Oncology. 2026;34(4):201367. doi:10.1016/j.omton.2026.201367
BibTeX
@article{Baugh2026,
author = {Baugh, Richard T and Barr, Tyler and Roundhill, Elizabeth A and Ismail, Fay and Volpato, Milene and Cook, Graham P and Burchill, Susan A and Errington-Mais, Fiona},
title = {ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {4},
pages = {201367},
doi = {10.1016/j.omton.2026.201367}
}
EUVIMED